FDA Accepts Daraxonrasib Application for Pancreatic Cancer
Daraxonrasib (RMC-6236) has been accepted by the FDA for review as a treatment for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The oral drug targets multiple RAS mutations, which are found in more than 90% of PDAC tumors. The application is being reviewed through the FDA Commissioner’s National Priority Voucher pilot program, which could shorten […]
FDA Accepts Daraxonrasib Application for Pancreatic Cancer Read More ยป